Small-Molecule Targeted Therapy: Kinase Inhibitors, BCL-2, PARP, and IMiDs

Correct Answer

C) Venetoclax

Rationale

Venetoclax is a selective BCL-2 inhibitor, also classified as a BH3 mimetic. Ibrutinib is a covalent Bruton's tyrosine kinase inhibitor. Olaparib is a PARP (poly ADP-ribose polymerase) inhibitor. Everolimus is an mTOR (mechanistic target of rapamycin) inhibitor. Class membership is sufficient to answer this question.

Correct Answer

A) Ibrutinib

Rationale

Ibrutinib is a covalent, irreversible Bruton's tyrosine kinase inhibitor and the first approved agent in this class. Venetoclax is a BCL-2 inhibitor. Palbociclib is a CDK4/6 (cyclin-dependent kinase 4 and 6) inhibitor. Idelalisib is a PI3K-delta (phosphoinositide 3-kinase delta) inhibitor.

Correct Answer

D) Alpelisib

Rationale

Alpelisib selectively inhibits the PI3K-alpha isoform and is approved for PIK3CA-mutant, estrogen receptor-positive, HER2-negative breast cancer. Idelalisib selectively inhibits the PI3K-delta isoform, which is the dominant isoform in B lymphocytes. Everolimus inhibits mTOR (mechanistic target of rapamycin), a kinase downstream of PI3K. Ibrutinib inhibits Bruton's tyrosine kinase, a distinct B-cell signaling kinase.

Correct Answer

B) Carfilzomib

Rationale

Carfilzomib is the second-generation, irreversible proteasome inhibitor — it forms a permanent covalent bond with the proteasome beta-5 subunit, providing sustained inhibition between doses. Bortezomib is a first-generation reversible proteasome inhibitor. Ixazomib is the oral, reversible proteasome inhibitor. Lenalidomide is an immunomodulatory drug and is not a proteasome inhibitor.

Correct Answer

C) Palbociclib

Rationale

Palbociclib is a CDK4/6 (cyclin-dependent kinase 4 and 6) inhibitor approved in combination with endocrine therapy for hormone receptor-positive, HER2-negative breast cancer. Venetoclax is a BCL-2 inhibitor. Everolimus is an mTOR inhibitor. Ibrutinib is a Bruton's tyrosine kinase inhibitor.

Correct Answer

A) Lenalidomide

Rationale

Lenalidomide is an immunomodulatory drug (IMiD), a class that also includes thalidomide and pomalidomide. These agents share a common mechanism involving cereblon binding and neo-substrate degradation. Bortezomib is a proteasome inhibitor. Venetoclax is a BCL-2 inhibitor. Ibrutinib is a Bruton's tyrosine kinase inhibitor.

Correct Answer

D) Vemurafenib occupies one copy of a RAF dimer, driving transactivation of the partner RAF copy and paradoxically amplifying downstream ERK signaling through the intact RAF-MEK-ERK cascade

Rationale

BRAF inhibitors such as vemurafenib are selective for mutant BRAF V600E, which signals as a monomer. In cells carrying activating mutations in rat sarcoma viral proto-oncogene family members (such as KRAS), RAF proteins signal as dimers. When vemurafenib occupies one member of a RAF dimer, it drives transactivation of the partner RAF copy through a conformational mechanism, paradoxically amplifying ERK phosphorylation and downstream proliferative signaling rather than suppressing it. This produces cutaneous squamous cell carcinomas and accelerates growth of any pre-existing rat sarcoma viral proto-oncogene-mutant tumor. Adding a MEK inhibitor downstream suppresses this paradoxical ERK activation and is required whenever a BRAF inhibitor is used. Vemurafenib does not bind KRAS directly, does not accumulate due to pharmacokinetic interactions with KRAS mutations, and the primary mechanism of paradoxical activation operates through RAF transactivation rather than EGFR feedback.

Correct Answer

B) Alpelisib inhibits PI3K-alpha in insulin-sensitive tissues including adipose tissue, liver, and skeletal muscle, impairing insulin-mediated glucose uptake and producing insulin resistance

Rationale

PI3K-alpha is a critical component of the insulin signaling pathway in metabolically active tissues — adipose tissue, liver, and skeletal muscle. Insulin activates PI3K-alpha, which generates phosphatidylinositol (3,4,5)-trisphosphate and propagates signals through AKT that enable glucose transporter translocation to the cell surface and cellular glucose uptake. Alpelisib inhibits PI3K-alpha in these tissues, impairing insulin's ability to promote glucose uptake and producing insulin resistance. The mechanism is not impaired insulin secretion — beta cells continue secreting insulin but peripheral tissues cannot respond to it. Mandatory fasting glucose monitoring before each cycle is required. Stimulating glucagon secretion and direct beta-cell secretory failure are mechanisms distinct from the insulin resistance observed with alpelisib. FOXO1 effects represent one downstream consequence, but the primary clinical mechanism is insulin resistance in peripheral tissues, not isolated hepatic gluconeogenesis.

Correct Answer

C) Venetoclax selectively inhibits BCL-2, which tumor cells with high BCL-2 expression depend on for survival; rapid full-dose initiation causes simultaneous lysis of a large number of tumor cells, releasing intracellular contents and precipitating tumor lysis syndrome

Rationale

BCL-2 is an anti-apoptotic protein overexpressed in chronic lymphocytic leukemia and other B-cell malignancies. Venetoclax displaces pro-apoptotic proteins from BCL-2, triggering rapid simultaneous apoptosis of BCL-2-dependent tumor cells. In patients with high tumor burden, starting at full dose causes the rapid lysis of a large mass of cells simultaneously, releasing potassium, phosphate, uric acid, and nucleic acids into the circulation faster than the kidneys can clear them. The resulting tumor lysis syndrome — hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia — can cause acute kidney injury, cardiac arrhythmia, and seizures within hours of the first dose. The ramp-up schedule reduces the pace of cell lysis at any given time, preventing this metabolic emergency. The ramp-up is not a pharmacokinetic strategy for achieving therapeutic concentrations, is not related to autoinduction, and is not driven by neutropenia recovery.

Correct Answer

B) Normal cells have two functional copies of BRCA2 and can repair double-strand deoxyribonucleic acid breaks via homologous recombination; BRCA2-mutant cancer cells lack this repair pathway, so unrepaired double-strand breaks from PARP inhibition accumulate and cause selective cancer cell death

Rationale

Synthetic lethality is the principle that two individually tolerated deficiencies combine to produce cell death. PARP1 and PARP2 repair single-strand breaks via the base excision repair pathway. When PARP is inhibited, single-strand breaks accumulate and are converted to double-strand breaks during deoxyribonucleic acid replication. Normal cells with intact BRCA2 repair these double-strand breaks accurately via homologous recombination. BRCA2-mutant cancer cells lack functional homologous recombination — the double-strand breaks cannot be repaired and lethal chromosomal instability results. Normal cells with two functional BRCA2 copies tolerate PARP inhibition because their homologous recombination pathway compensates. BRCA2-mutant cancer cells overexpress PARP1 in some contexts but PARP overexpression is not the mechanism of sensitivity. Olaparib does not undergo selective cellular uptake mediated by the mutant BRCA2 protein. The deficiency in BRCA2-mutant cells is in homologous recombination, which repairs double-strand breaks — not base excision repair, which handles single-strand breaks.

Correct Answer

D) Subcutaneous and intravenous administration of bortezomib produce equivalent systemic drug exposure and equivalent antitumor efficacy, but subcutaneous administration produces substantially lower rates of severe peripheral neuropathy

Rationale

Pharmacokinetic studies established that subcutaneous bortezomib produces systemic drug exposure equivalent to intravenous administration — area under the concentration-time curve values are comparable — and equivalent rates of major molecular response and overall response in myeloma. However, the incidence of grade 3 or higher peripheral neuropathy is approximately 6 percent with subcutaneous administration versus approximately 16 percent with intravenous administration. The proposed mechanism is that subcutaneous delivery avoids the high peak plasma concentrations produced by intravenous bolus dosing, reducing bortezomib-mediated damage to dorsal root ganglion neurons. Subcutaneous bortezomib does not have higher bioavailability, does not bypass renal clearance (bortezomib is primarily hepatically metabolized), and does not require lower total doses — the same dose is used by both routes.

Correct Answer

A) Idelalisib inhibits PI3K-delta, the dominant phosphoinositide 3-kinase isoform in T lymphocytes and regulatory T cells, causing immune dysregulation that impairs control of opportunistic pathogens including Pneumocystis jirovecii

Rationale

PI3K-delta is expressed predominantly in hematopoietic cells, including B cells and T cells. Idelalisib's inhibition of PI3K-delta in T lymphocytes — particularly regulatory T cells — causes immune dysregulation characterized by hepatotoxicity, immune-mediated colitis resembling inflammatory bowel disease, and serious opportunistic infections. Loss of regulatory T-cell function impairs immune surveillance and control of latent and environmental pathogens including Pneumocystis jirovecii, cytomegalovirus, and others. Pneumocystis jirovecii pneumonia prophylaxis with trimethoprim-sulfamethoxazole is mandatory throughout idelalisib therapy. The prophylaxis is given because of immune impairment, not because idelalisib increases trimethoprim-sulfamethoxazole plasma levels through cytochrome P450 inhibition — that interaction would be a safety concern, not a rationale for prescribing the combination. Idelalisib does not primarily work through humoral immunity depletion or neutropenia.

Correct Answer

C) Ibrutinib's off-target inhibition of ITK (interleukin-2-inducible T-cell kinase) and C-terminal Src kinase in atrial cardiomyocytes disrupts cardioprotective signaling pathways, promoting atrial fibrillation

Rationale

Atrial fibrillation is a recognized adverse effect of ibrutinib occurring in 6 to 16 percent of patients and is substantially more common with ibrutinib than with the more selective second-generation agents acalabrutinib and zanubrutinib. The mechanism is attributed to ibrutinib's off-target inhibition of ITK (interleukin-2-inducible T-cell kinase) and C-terminal Src kinase in atrial cardiomyocytes, which disrupts cardioprotective kinase signaling and predisposes to atrial arrhythmia. The lower rate of atrial fibrillation with acalabrutinib and zanubrutinib — which are more selective for Bruton's tyrosine kinase and have less ITK inhibition — supports off-target kinase inhibition as the mechanism. Ibrutinib does not produce its atrial fibrillation through QTc prolongation via hERG channel blockade, through direct Bruton's tyrosine kinase-mediated calcium dysregulation in cardiomyocytes, or through adrenal catecholamine release.

Correct Answer

A) Enasidenib inhibits IDH2, reducing 2-hydroxyglutarate production and restoring myeloid differentiation capacity; rapid differentiation of leukemic blasts releases pro-inflammatory cytokines that produce an inflammatory syndrome affecting multiple organs

Rationale

IDH2 gain-of-function mutations generate the oncometabolite 2-hydroxyglutarate, which blocks normal myeloid differentiation and maintains leukemic blasts in an immature state. Enasidenib inhibits mutant IDH2, suppresses 2-hydroxyglutarate production, and restores differentiation capacity. When leukemic blasts differentiate rapidly after inhibitor initiation, the maturing myeloid cells release large amounts of pro-inflammatory cytokines in a short time, producing differentiation syndrome — a potentially life-threatening inflammatory syndrome with fever, dyspnea, hypotension, bilateral pulmonary infiltrates, pleural and pericardial effusions, and acute kidney injury, typically occurring within 5 to 12 weeks of starting therapy. Treatment is dexamethasone 10 mg intravenously twice daily until resolution. The syndrome is caused by the therapeutic effect of differentiation, not by direct pulmonary toxicity, reactive metabolites, or impaired normal hematopoiesis.

Correct Answer

D) Reduce the bortezomib dose by 25 percent and switch to subcutaneous administration, which produces equivalent antitumor efficacy with substantially lower rates of severe peripheral neuropathy

Rationale

Bortezomib peripheral neuropathy is dose-limiting and cumulative. For grade 2 peripheral neuropathy with pain, the management protocol calls for a 25 percent dose reduction and continuation of therapy. Switching to the subcutaneous route is also appropriate because subcutaneous administration produces systemic exposure equivalent to intravenous dosing but substantially lower rates of grade 3 or higher peripheral neuropathy — approximately 6 percent versus 16 percent with the intravenous route. Permanent discontinuation is reserved for grade 4 neuropathy; grade 2 painful neuropathy calls for modification, not termination. Grade 2 peripheral neuropathy does require dose modification — continuing without change does not meet the standard of care. Switching to a different proteasome inhibitor class is not required; the combination of dose reduction and subcutaneous administration often allows continued bortezomib therapy.

Correct Answer

B) Hold ribociclib until the corrected QT interval returns to below 480 milliseconds, then restart at a reduced dose

Rationale

Ribociclib prolongs the corrected QT interval by inhibiting cardiac potassium channels, an off-target effect that requires mandatory baseline and follow-up electrocardiogram monitoring. The protocol threshold is a corrected QT interval of 480 milliseconds: when the corrected QT interval reaches or exceeds 480 milliseconds, ribociclib must be held until the corrected QT interval returns below 480 milliseconds, then restarted at the next lower dose level. This patient's corrected QT interval of 485 milliseconds exceeds the threshold and mandates drug interruption. Continuing at the same dose ignores a threshold that exists to prevent dangerous arrhythmia. Permanent discontinuation is required only for recurrent corrected QT prolongation above 480 milliseconds after dose reduction, or for a corrected QT interval above 500 milliseconds. Empirical potassium supplementation alone does not address the drug-induced channel blockade and would not be appropriate when electrolytes are already normal.

Correct Answer

A) Reduce the venetoclax dose to 70 mg daily and continue posaconazole, because posaconazole inhibits cytochrome P450 3A4 and substantially increases venetoclax plasma concentrations

Rationale

Venetoclax is a cytochrome P450 3A4 substrate. Posaconazole is a strong cytochrome P450 3A4 inhibitor that substantially increases venetoclax plasma exposure — studies show it increases venetoclax exposure approximately fivefold or more, which markedly amplifies the risk of tumor lysis syndrome by accelerating cell lysis at a rate beyond what the ramp-up schedule was designed to manage. The approved management for concurrent posaconazole use is to reduce the venetoclax dose to 70 mg and continue both drugs rather than stopping venetoclax. Strong inhibitors such as ketoconazole and clarithromycin are contraindicated during ramp-up because the interaction magnitude is too large to manage safely with dose reduction; posaconazole, though a strong inhibitor, has a sufficiently characterized interaction to allow venetoclax continuation at 70 mg under close monitoring. Continuing venetoclax at 100 mg without dose adjustment would expose the patient to dangerously elevated venetoclax concentrations. Doubling the antifungal dose does not reverse enzyme inhibition and has no pharmacological rationale.

Correct Answer

C) Lenalidomide redirects the CRL4-cereblon ubiquitin ligase to degrade casein kinase 1 alpha 1; because the gene encoding casein kinase 1 alpha 1 resides on chromosome 5q and del(5q) cells retain only one functional copy, further reduction of the enzyme is lethal specifically to the del(5q) clone

Rationale

Lenalidomide binds cereblon and redirects the CRL4-cereblon ubiquitin ligase complex to degrade neo-substrates not normally targeted by this complex. In del(5q) myelodysplastic syndrome, the relevant neo-substrate is casein kinase 1 alpha 1, whose gene resides on chromosome 5q. Because del(5q) cells have lost one copy of chromosome 5q, they are hemizygous for the casein kinase 1 alpha 1 gene and express less enzyme than normal cells. Lenalidomide-driven degradation of the remaining casein kinase 1 alpha 1 protein reduces the enzyme below a threshold tolerable in cells with two copies but lethal in hemizygous del(5q) clones. Normal cells with two copies of the gene tolerate the degradation. This is a form of synthetic lethality: the chromosomal deletion and drug-induced degradation combine to selectively kill the del(5q) clone. Cereblon overexpression, vascular endothelial growth factor suppression, and deoxyribonucleic acid repair deficiency are not the mechanisms of del(5q) selectivity.